London Genetics and Astrimmune to Collaborate on Cancer Vaccine

LONDON and NOTTINGHAM, England, November 12, 2010 - London Genetics Limited, an expert in the use of
pharmacogenetics in clinical drug discovery and development, and Astrimmune,
which is focused on gastrointestinal cancers, are pleased to announce that
they have entered into a collaboration to plan a biomarker identification
programme. The plan, for Astrimmune's early-stage pancreatic cancer vaccine
candidate, will be used in applications for further funding of its
development. Financial terms were not disclosed.

Astrimmune's vaccine candidate induces the production of
antibodies against gastrin, a hormone which is known to stimulate the growth
of many types of gastrointestinal cancer. Since differential response rates
have been observed in clinical trials of other gastrin-blocking products,
with some patients responding very well and others hardly at all, there is a
clear need for biomarkers to help identify those patients most likely to
benefit from Astrimmune's product. For example, there is a possibility that
the variable response rates may have been due in part to the inclusion of
some patients with gastrin-insensitive tumours, or those not able to respond
immunologically.

Under the terms of the collaboration, which is supported by a
grant from the UK East Midlands Development Agency, London Genetics and
Astrimmune will put together a proposal for identification of biomarkers
predictive of clinical response. London Genetics' seven academic partners,
which have an annual research budget of over GBP650m, are able to provide
expertise in areas such as tumour biopsy samples and animal models, as well
as expertise in the genetics of immune responses to cancer vaccines.

Dominique Kleyn, CEO of London Genetics, said, 'This
collaboration is a significant pharmacogenetics development opportunity, and
we are pleased to be working with Astrimmune on this important project. As
exemplified by our recent collaboration with Diaceutics and increasingly
recognised by the biopharmaceutical industry, pharmacogenetics, biomarkers
and patient stratification are becoming an important part of the drug
discovery and development process. London Genetics' network of over 3,000
academic groups makes it an ideal partner for pharma and biotech companies in
this work.'

Fred Jacobs, Managing Director of Astrimmune, said,
'Pancreatic cancer is an area of serious unmet medical need, with a five-year
survival rate of around 5% and few treatment options. Availability of a
biomarker to select those patients mostly likely to benefit from Astrimmune's
vaccine candidate can be expected to expedite the development of this product
and increase its chances of coming to market in the future. London Genetics
is an expert in this area and Astrimmune is delighted to be working with the
company on this important part of the project development.'

About London Genetics: London Genetics Limited, a
not-for-profit company, is an expert in the use of pharmacogenetics in
clinical drug discovery and development. Established in 2007 with funding
from the London Development Agency, its seven founding partners are leading
London academic and medical institutions with clinical and genetic expertise
and significant patient resources. The company provides pharmaceutical and
biotechnology companies with access to this expertise and resource, as well
as providing strategic advice on the application of pharmacogenetics for
successful drug development. LGL has broad therapeutic expertise, based on
its access to 3,000 academic groups with a GBP650m annual research spend.
Recent deals by London Genetics include a partnership with Diaceutics to
accelerate biomarker development in the biopharmaceutical industry. LGL is
based in central London and has ISO 9001 accreditation. For further
information, please go to www.londongenetics.com

About Astrimmune: Astrimmune (Company Registration: 06379008),
is a limited, social enterprise company developing treatments for
gastrointestinal cancers. Astrimmune is focussed on the elimination of cancer
growth factors that are not yet commercialised and is progressing a new
immunogen vaccine candidate for use in gastro-intestinal cancers. The
distillation of their prior knowledge, coupled with a research programme to
refine patient selection to identify the most responsive patients, provides
for an accelerated, low cost development path with an increased chance of
successful product registration in the EU and the US. For further
information, please go to astrimmune.blogspot.com/

    For further information please contact:

    London Genetics Ltd

    Dominique Kleyn, CEO
    +44(0)207-594-1838

    Emma Palmer Foster, Strategic Communications Consultant
    +44(0)7880-787185

    communications@londongenetics.com

    Astrimmune

    Fred Jacobs, Managing Director
    +44(0)7989-386326

For further information please contact: London Genetics Ltd, Dominique Kleyn, CEO, +44(0)207-594-1838; Emma Palmer Foster, Strategic Communications Consultant, +44(0)7880-787185, communications at londongenetics.com; Astrimmune: Fred Jacobs, Managing Director +44(0)7989-386326